PCSK9 and hyperlipidemia: As such, many patients require adjunct therapies to properly control hyperlipidemia, including niacin, bile acid sequestrants, fibric acids, and cholesterol absorption inhibitor ezetimibe, as well as the recently approved class PCSK9 inhibitors.